858366-82-2

Upstream product

• 56577-28-7 methyl (2S,3S)-2-hydroxy-3-methylpentanoate 
• 488-15-3 (2S,3S)-2-Hydroxy-3-methylpentanoic acid 
• 73-32-5 L-isoleucine 
• 858366-77-5 methyl (2S,3S)-2-(3,5-difluorobenzyloxy)-3-methylpentanoate 
• 862666-05-5 (2S,3S)-2-(3,5-Difluoro-benzyloxy)-3-methyl-pentan-1-ol 

Downstream Products

• 858366-92-4 (3S,4S)-3-(3,5-Difluoro-benzyloxy)-4-methyl-1-nitro-hexan-2-ol 
• 858366-98-0 1-{[(E,3S,4S)-4-methyl-1-nitrohex-1-en-3-yloxy]methyl}-3,5-difluorobenzene 
• 858367-20-1 (2S,3R,4S,5S)-3-[(1S,2S)-1-(3,5-Difluoro-benzyloxy)-2-methyl-butyl]-4-nitro-5-phenyl-pyrrolidine-2-carboxylic acid methyl ester 
• 858367-09-6 (2S,3R,4S,5S)-3-[(1S,2S)-1-(3,5-difluorobenzyloxy)-2-methylbutyl]-4-nitro-5-phenylpyrrolidine-2-carboxylic acid 
• 868526-28-7 ({(2S,3R,4S,5S)-3-[(1S,2S)-1-(3,5-Difluoro-benzyloxy)-2-methyl-butyl]-4-nitro-5-phenyl-pyrrolidine-2-carbonyl}-amino)-acetic acid methyl ester 

Relevant academic research and scientific papers

Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders

This invention relates to nitroproline derivative compounds and procedures for their preparation and the preparation of pharmaceutical compositions containing the compounds. The invention also relates to the administration of compounds of the invention as

Application of stereocontrolled stepwise [3+2] cycloadditions to the preparation of inhibitors of α4β1-integrin- mediated hepatic melanoma metastasis

(Chemical Equation Presented) Inhibitors of the interaction between protein VLA-4 and its natural ligand VCAM-1 have been designed, even though the structure of the protein remains unresolved. The rational design relied on the simulation of the steric and electronic properties of the active loop of VCAM-1, whose structure is known (see picture), and the inhibitors were readily prepared by stereoselective stepwise [3+2] cycloadditions.